Pfizer Inc. boasts deep pockets and R&D expertise in a broad range of therapeutic areas, but it generally isn’t regarded yet as one of the big players in non-alcoholic steatohepatitis (NASH). However, the big pharma has four NASH candidates in clinical development – each of which takes a hepatic fat-reduction approach to the multifactorial disease – and has begun talking up its first-in-class, Phase II ketohexokinase (KHK) inhibitor for the disease.
Pfizer presented data from a 53-patient Phase II study of PF-06835919 at the European Association for the Study of the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
